| 发明名称 | Treatment of cancer | ||
| 摘要 | The present invention relates to agents for use in treating cancer. The agent to be used is an antagonist of Dsg2, wherein the antagonist modulates the function of the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO:1), or a fragment or variant thereof, of the EC2 domain of Dsg2. Also included in the invention are specific polypeptides and pharmaceutical preparations. Also included in the invention is a method of screening for antagonists of Dsg2, wherein the antagonist modulates the function of the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO: 1), or a fragment or variant thereof, of the EC2 domain of Dsg2. | ||
| 申请公布号 | US9376492(B2) | 申请公布日期 | 2016.06.28 |
| 申请号 | US201013497562 | 申请日期 | 2010.09.22 |
| 申请人 | Asclepiumm Limited | 发明人 | Chen Min-Che |
| 分类号 | A61K39/395;C07K16/28;C07K14/705;A61P35/04;G01N33/50;A61K38/00 | 主分类号 | A61K39/395 |
| 代理机构 | Michael Best & Friedrich LLP | 代理人 | Michael Best & Friedrich LLP |
| 主权项 | 1. A method of treating cancer comprising administering to a subject having cancer a therapeutically effective quantity of an antagonist of desmoglein 2 (Dsg2), wherein said antagonist is an antibody or antibody fragment that specifically binds to the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO: 1), or a biologically active fragment thereof, of the non-cell adhesion recognition (non-CAR) sequence of the EC2 domain of Dsg2, and wherein said antagonist reduces the epithelial-mesenchymal transition (EMT) promoting function of Dsg2. | ||
| 地址 | Manchester GB | ||